# Tesamorelin vs Sermorelin: What the Evidence Shows About the Two GHRH Analogues

> Tesamorelin vs Sermorelin: full-length stabilized GHRH(1-44) vs truncated GHRH(1-29), DPP-IV resistance, the human evidence base, and the regulatory difference, compared from the literature.

Two GHRH analogues compared as typed records — the full-length stabilized GHRH(1-44) tesamorelin against the truncated GHRH(1-29) sermorelin — on sequence, DPP-IV resistance, evidence base, and regulatory status.

## The short version

Tesamorelin vs sermorelin is a comparison of two molecules that do the same basic thing — tell the pituitary to release growth hormone — but are built differently. Sermorelin is a short fragment of the natural hormone (the first 29 amino acids). Tesamorelin is the full-length hormone (all 44 amino acids) with a chemical cap that protects it from being broken down, so it lasts longer in the body. The bigger difference is the evidence: tesamorelin has a large set of human trials and an FDA approval (for HIV-associated lipodystrophy only), which shapes how each is studied.

## Structure: full-length GHRH(1-44) vs truncated GHRH(1-29)

The core structural difference between tesamorelin and sermorelin is length and stabilization. Tesamorelin is a stabilized full-length GHRH(1-44) analogue — all 44 residues of the natural hormone — whereas sermorelin is the truncated GHRH(1-29), the shortest fragment that retains GHRH activity [12]. Both act on the same target, the GHRH receptor on pituitary somatotrophs.

The decisive feature is what tesamorelin adds: an N-terminal trans-3-hexenoic acid modification that confers resistance to dipeptidyl peptidase-IV (DPP-IV), the protease that rapidly inactivates native GHRH and, by extension, unmodified GHRH peptides [10][12]. That cap is why tesamorelin survives in plasma long enough to produce the sustained downstream GH/IGF-1 signal documented in its trials, rather than being clipped within minutes [10].

## Evidence base: where the two diverge most

The largest difference between tesamorelin and sermorelin is the depth of the human evidence behind tesamorelin specifically. Tesamorelin carries two pivotal Phase 3 RCTs in HIV-associated lipodystrophy — the 26-week NEJM trial (n=412; VAT -15.2% vs +5.0% placebo; IGF-1 +81.0%) [5] and the 52-week program (sustained -18% VAT) [6] — plus a JAMA hepatic-fat RCT [7], a mechanistic healthy-men study [8], a dedicated type-2-diabetes safety trial [2], and a 2026 five-RCT meta-analysis [15].

A clinical review explicitly frames tesamorelin as the stabilized full-length GHRH(1-44) analogue distinct from sermorelin's truncated GHRH(1-29), summarizing that Phase 3 visceral-fat evidence [12]. Tesamorelin was also developed on the rationale that GRF analogues may be better tolerated than recombinant human growth hormone [13]. This page compares the tesamorelin record; it does not assert head-to-head trial data against sermorelin, because no such direct comparison anchors this digest — the divergence is in design and in the regulatory dossier, not in a single comparative RCT.

## Regulatory status: the practical difference

On regulatory standing, tesamorelin is FDA-approved (NDA 022505, 2010) for one indication — reducing excess abdominal fat in HIV-associated lipodystrophy — and off-label for everything else [4]. It is prohibited in sport under WADA category S2 as a GHRH analogue. That approval, narrow as it is, is the clearest line between the two: it means tesamorelin has a characterized finished product, a label with enumerated contraindications, and a pharmacovigilance record behind that single indication [1].

The comparison should not be read as a recommendation of either compound for any use. Both are GHRH-pathway agents; tesamorelin's distinction is its DPP-IV-resistant full-length design and the unusually deep trial record that earned its single approval. Where that record stops — non-HIV populations, long-term oncologic safety — it stops for tesamorelin too.

---

The tesamorelin literature read as a validated record — every figure typed to its field and carried back to its study, the FDA scope (HIV-associated lipodystrophy only), the labeled contraindications, and the off-label edge surfaced as the record's leading status; a digest that flags before it reports, never a clinic, a vendor, or a prescription.